Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Louie Linda H.

2. Date of Event Requiring Statement (MM/DD/YYYY) 7/23/2020

3. Issuer Name and Ticker or Trading Symbol

AMGEN INC [AMGN]

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
VP, Finance & CAO /

(Street)

THOUSAND OAKS, CA 91320

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6175 ⁽¹⁾⁽²⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Nqso (Right to Buy)	5/3/2018 ⁽³⁾	5/3/2026	Common Stock	370	$156.35	D
Nqso (Right to Buy)	5/1/2019 ⁽⁴⁾	5/1/2027	Common Stock	1633	$162.60	D
Nqso (Right to Buy)	4/27/2020 ⁽⁵⁾	4/27/2028	Common Stock	1301	$177.46	D
Nqso (Right to Buy)	5/3/2021 ⁽⁶⁾	5/3/2029	Common Stock	1723	$177.31	D
Nqso (Right to Buy)	5/5/2022 ⁽⁷⁾	5/5/2030	Common Stock	1417	$236.36	D

Explanation of Responses:
(1)	These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 63 RSUs which fully vest on 5/1/2021; 114 RSUs which vest in two installments of 56 on 4/27/2021 and 58 on 4/27/2022; 197 RSUs which vest in two installments of 65 on 5/3/2021 and 5/3/2022 and one installment of 67 on 5/3/2023; and 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
(2)	These shares include 22 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
(3)	370 non-qualified stock options have vested and are exercisable.
(4)	1,077 of these non-qualified stock options have vested and are exercisable and 556 of these options will vest and become exercisable on 5/1/2021.
(5)	429 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 429 on 4/27/2021 and 443 on 4/27/2022.
(6)	These non-qualified stock options will vest and become exercisable in three installments of 568 on 5/3/2021, 569 on 5/3/2022 and 586 on 5/3/2023.
(7)	These non-qualified stock options will vest and become exercisable in three installments of 467 on 5/5/2022, 468 on 5/5/2023 and 482 on 5/5/2024.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Louie Linda H. ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320			VP, Finance & CAO